John Overdeck’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.5M | Buy |
4,091,043
+3,476,244
| +565% | +$31.1M | 0.03% | 682 |
|
|
2026
Q1 | $5M | Sell |
614,799
-9,013
| -1% | -$81.7K | ﹤0.01% | 1976 |
|
|
2025
Q4 | $4.19M | Sell |
623,812
-78,188
| -11% | -$589K | 0.01% | 1868 |
|
|
2025
Q3 | $6.09M | Buy |
702,000
+162,754
| +30% | +$1.27M | 0.01% | 1309 |
|
|
2025
Q2 | $3.4M | Buy |
539,246
+299,061
| +125% | +$1.98M | 0.01% | 1486 |
|
|
2025
Q1 | $1.54M | Buy |
240,185
+209,278
| +677% | +$1.73M | ﹤0.01% | 1903 |
|
|
2024
Q4 | $248K | Sell |
30,907
-730,029
| -96% | -$7.04M | ﹤0.01% | 2807 |
|
|
2024
Q3 | $9.61M | Buy |
760,936
+261,528
| +52% | +$3.38M | 0.02% | 776 |
|
|
2024
Q2 | $6.32M | Buy |
+499,408
| New | +$5.02M | 0.01% | 902 |
|
|
2023
Q2 | – | Sell |
-363,036
| Closed | -$2.52M | – | 3190 |
|
|
2023
Q1 | $2.52M | Sell |
363,036
-647,956
| -64% | -$5.96M | 0.01% | 1250 |
|
|
2022
Q4 | $10.4M | Buy |
+1,010,992
| New | +$17.8M | 0.03% | 540 |
|
|
2020
Q4 | – | Sell |
-144,079
| Closed | -$15.6M | – | 3625 |
|
|
2020
Q3 | $15.6M | Buy |
+144,079
| New | +$17.6M | 0.06% | 365 |
|
|
2019
Q3 | – | Sell |
-53,647
| Closed | -$314K | – | 3703 |
|
|
2019
Q2 | $314K | Sell |
53,647
-62,141
| -54% | -$489K | ﹤0.01% | 2840 |
|
|
2019
Q1 | $1.28M | Sell |
115,788
-48,340
| -29% | -$1.53M | ﹤0.01% | 1685 |
|
|
2018
Q4 | $6.04M | Buy |
164,128
+113,404
| +224% | +$4.4M | 0.02% | 718 |
|
|
2018
Q3 | $1.91M | Sell |
50,724
-40,517
| -44% | -$1.14M | 0.01% | 1517 |
|
|
2018
Q2 | $2.44M | Buy |
91,241
+78,869
| +637% | +$2.67M | 0.01% | 1480 |
|
|
2018
Q1 | $520K | Buy |
12,372
+3,692
| +43% | +$148K | ﹤0.01% | 2449 |
|
|
2017
Q4 | $215K | Buy |
+8,680
| New | +$212K | ﹤0.01% | 2893 |
|
|
2017
Q1 | – | Sell |
-1,618
| Closed | -$41K | – | 3187 |
|
|
2016
Q4 | $41K | Buy |
+1,618
| New | +$47.2K | ﹤0.01% | 3013 |
|
|
2016
Q3 | – | Sell |
-685
| Closed | -$100K | – | 3298 |
|
|
2016
Q2 | $100K | Buy |
+685
| New | +$78.5K | ﹤0.01% | 2821 |
|
|
2015
Q4 | – | Sell |
-25,669
| Closed | -$3.63M | – | 2890 |
|
|
2015
Q3 | $3.63M | Buy |
+25,669
| New | +$5.76M | 0.02% | 620 |
|
|
2013
Q4 | – | Sell |
-713
| Closed | -$45K | – | 2316 |
|
|
2013
Q3 | $45K | Buy |
+713
| New | +$40.2K | ﹤0.01% | 1785 |
|
Other funds holding NVAX
SCM
S
John Overdeck's NVAX Position: Q2 2026 in Review
John Overdeck increased its Novavax (NVAX) stake by 565% in Q2 2026, buying an estimated $31.1M and bringing the position to 4,091,043 shares worth $38.5M. The position accounts for 0.03% of the portfolio, ranked #682.
John Overdeck first reported a position in NVAX in Q3 2013 and has held it in 23 quarters since. 264 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- John Overdeck held 4,091,043 shares of Novavax worth $38.5M as of Q2 2026.
- John Overdeck bought 3,476,244 Novavax shares in Q2 2026, an estimated $31.1M.
- Novavax made up 0.03% of John Overdeck's portfolio in Q2 2026, its #682 holding.
- John Overdeck first reported a position in Novavax in Q3 2013 and has held it in 23 quarters since.
- 264 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.